(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.34%) $82.73
(6.55%) $2.05
(0.01%) $2 347.50
(-0.35%) $27.44
(4.08%) $959.75
(-0.24%) $0.933
(-0.34%) $10.99
(-0.53%) $0.796
(1.55%) $93.30
4.57% $ 23.13
@ $31.40
Ausgestellt: 11 Mär 2024 @ 15:33
Rendite: -26.34%
Vorheriges Signal: Mär 8 - 19:41
Vorheriges Signal:
Rendite: -7.29 %
Live Chart Being Loaded With Signals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma...
Stats | |
---|---|
Tagesvolumen | 1.08M |
Durchschnittsvolumen | 1.27M |
Marktkapitalisierung | 2.87B |
EPS | $-1.030 ( 2024-02-06 ) |
Nächstes Ertragsdatum | ( $-0.0600 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.35 |
ATR14 | $0.0410 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Hamilton James C | Sell | 6 000 | Common Stock |
2024-03-20 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-19 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-18 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-15 | Lu Hongbo | Sell | 0 | Common Stock |
INSIDER POWER |
---|
15.59 |
Last 100 transactions |
Buy: 963 379 | Sell: 694 332 |
Volumen Korrelation
Arrowhead Pharmaceuticals Korrelation
10 Am meisten positiv korreliert | |
---|---|
PRDS | 0.893 |
RDUS | 0.892 |
EYPT | 0.874 |
JAKK | 0.869 |
BIIB | 0.853 |
FSV | 0.851 |
RGF | 0.848 |
RILYL | 0.848 |
COUP | 0.846 |
MDXH | 0.845 |
10 Am meisten negativ korreliert | |
---|---|
GMII | -0.885 |
MTSI | -0.87 |
MEUSW | -0.861 |
ALGM | -0.86 |
DHC | -0.86 |
XOG | -0.852 |
SBBP | -0.85 |
BGCP | -0.849 |
VTRU | -0.849 |
INOD | -0.845 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Arrowhead Pharmaceuticals Korrelation - Währung/Rohstoff
Arrowhead Pharmaceuticals Finanzdaten
Annual | 2023 |
Umsatz: | $240.74M |
Bruttogewinn: | $228.24M (94.81 %) |
EPS: | $-1.920 |
FY | 2023 |
Umsatz: | $240.74M |
Bruttogewinn: | $228.24M (94.81 %) |
EPS: | $-1.920 |
FY | 2022 |
Umsatz: | $243.23M |
Bruttogewinn: | $232.81M (95.72 %) |
EPS: | $-1.670 |
FY | 2021 |
Umsatz: | $138.29M |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-1.360 |
Financial Reports:
No articles found.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.